Immunomic Therapeutics investigational UNITEplatform is founded in a combination of complementary technologies and capabilities: ITIs proprietary lysosomal targeting technology, optimal use of adjuvants, antigen selection and optimization, a breadth of delivery methods, and the ability to manufacture material at a large scale. Find your private company bowl on Fishbowl, join the hottest conversation with your colleagues anonymously. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms Recruiters: We do not accept unsolicited resumes from any source other than directly from the candidate. Rockville's Immunomic Therapeutics Inc. is on track to go public later this year, after Covid-19 threw a wrench in the vaccine maker's initial timeline. ITI-1001 is an alternative, cell-free approach to treating GBM. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. Immunomic Therapeutics, Inc. (ITI) is a privately held, clinical stage biotechnology company pioneering the development of vaccines through its proprietary technology platform, UNiversal . Immunomic Therapeutics Company Profile: Valuation & Investors | PitchBook Active, Closed, Last funding round type (e.g. ITI-2000 HPV+ Tumors. mcarey@rxir.com For more information, please visit www.immunomix.com. For consideration, please send your company information, a copy of your standard search agreement, and references to: careers@immunomix.com. While the presence of the CMV pp65 antigen itself is expected to induce a general effector T cell response, fusion of the antigen to Lysosomal Associated Membrane Protein (LAMP) is intended to compel processing of the antigen through a pathway that presents antigens specifically to CD4+ T cells and results in a robust Th1- type response (Arruda, 2006). Proceeds from the financing will support the acceleration of ITI's Phase II clinical trial of ITI-1000 for the treatment of glioblastoma multiforme (GBM), advance its emerging pipeline, and expand upon the current applications of its UNITE platform. Seed, Series A, Private Equity), Alternate or previous names for the organization, Whether an Organization is for profit or non-profit, General contact email for the organization. ITI is using the UNITE platform to develop vaccines against various infectious diseases, SARS-CoV-2 (COVID-19) among them. ITI-1000 is a cell therapy powered by ITIs UNITE platform that is currently being evaluated in a Phase II clinical trial (ATTAC-II) in collaboration with researchers at the University of Florida (Dr. Duane Mitchell) and Duke University (Dr. John Sampson). All content is posted anonymously by employees working at Immunomic Therapeutics. Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines. Preclinical data is currently being developed to explore whether LAMP nucleic acid constructs may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. / Oct 13, 2015. For more information, please visit www.immunomix.com. Hum Vaccin Immunother. Immunomic Therapeutics Announces Close of $61.3M Financing This is the Immunomic Therapeutics company profile. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products . The company is developing three small molecule products; its lead development program, IMU-838, a selective . Arruda L.B., et al., Dendritic Cell-Lysosomal-Associated Membrane Protein (LAMP) and LAMP-1-HIV-1 Gag Chimeras Have Distinct Cellular Trafficking Pathways and Prime T and B Cell Responses to a Diverse Repertoire of Epitopes. Join to follow . Juniper Point Immunomic Therapeutics Announces the Appointment of Frances Harrison as 2020 Immunomic Therapeutics, Inc. All Rights Reserved. All answers shown come directly from Immunomic Therapeutics Reviews and are not edited or altered. ITI-1000 is being tested in a randomized, blinded, and placebo-controlled phase 2 study in patients with newly-diagnosed glioblastoma (GBM) that is anticipated to close in 2022. 858-366-3243, Internet Explorer presents a security risk. mcarey@rxir.com Claim your Free Employer Profile. UNITE has a robust history of applications in various therapeutic areas, including infectious diseases, oncology, allergy, and autoimmune diseases. We have significant capabilities in molecular biology, including nucleic acid vaccine design, immunology, and tumor mouse modeling. Cytokines secreted by CD4+ T cells, such as IFN, can also exert desirable effects on the tumor microenvironment. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including viral antigens, cancer antigens, neoantigens and antigen-derived antibodies as biologics. Curr Opin Immunol. GBM patients white blood cells are removed, matured into dendritic cells and vaccinated against the pp65 viral protein, then returned to the patient. ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. The oncogenes E6 and E7 in both HPV 16 and HPV 18 strains are well proven to be immunogenic, providing the support to develop this product.ITI-2000, delivered by needle and syringe as a self-amplifying construct, will be indicated for HPV-positive cancers. Mr. Stamper holds a Master of Biotechnology Enterprise and Entrepreneurship Degree (MBEE) from Johns Hopkins University, a Master of Science Degree in Biologics Engineering from Purdue University, and a Bachelor of Science Degree in Biochemistry from Indiana University. ITI is primarily focused on applying the UNITE platform to oncology, where it could potentially have broad applications, including antigen-derived antibodies as biologics. ITI granted Japanese animal health company, ZENOAQ (Nippon Zenyaku Kogyo Co., Ltd, Koriyama, Japan) an exclusive license to develop and commercialize its investigational DNA vaccine for canine atopic dermatitis and other companion animal allergies. ITI maintains its headquarters in Rockville, Maryland. Vaccine technology developed at Johns Hopkins could lead to - Hub It is important to note that, while the mechanism of lysosomal targeting appears to focus on enhancing presentation of antigen to CD4+ T cells and producing a Th1 type CD4+ T cell response (an aspect missing in other platforms), the UNITE platform, as a whole, is believed to induce a broad immune response and can result in enhanced CD8+ T cell responses as well. Prior to joining ITI, Mr. Stamper held director roles in manufacturing at Kite Pharma, a global biopharmaceutical company whose focus is cell therapy to treat and cure cancer. Immunomic Therapeutics Announces Presentation on Nucleic Acid-Based MiNA Therapeutics Limited Translation & Innovation Hub 84 Wood Lane London W12 0BZ United Kingdom. 438 followers 429 connections. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Immunomic Therapeutics Announces First Patient Dosed in Phase I 301-968-3501, ITI Media: 2020 Immunomic Therapeutics, Inc. All Rights Reserved. Additionally, our expanded capabilities allow us to work with our corporate partners to better understand and develop the manufacturing process and product testing assays. mkemp@immunomix.com ITI-1000 is a dendritic cell therapy comprised of autologous dendritic cells (DCs) loaded with messenger ribonucleic acid (mRNA) encoding the human Lysosomal Associated Membrane Protein (hLAMP) gene fused in frame to a human Cytomegalovirus (hCMV) matrix protein, pp65 gene (hLAMP:pp65) and subsequently administered with Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Tetanus/diphtheria (Td) toxoid which serve as adjuvants. See Immunomic Therapeutics funding rounds, investors, investments, exits and more. Immunomic Therapeutics, Inc. Glioblastoma Multiforme (GBM) - Immunomic Therapeutics GOLDEN, Colo. December 13, 2022 PharmaJet, a company that engineers precision delivery systems that overcome the challenges of vaccine and pharmaceutical companies, today announced that their partner Immunomic Therapeutics received FDA fast track designation (FTD) for the clinical study of their plasmid DNA vaccine ITI-3000 in patients with Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies, and animal health. Immunomic, Colmmune partner on cancer immunotherapy By The Science Advisory Board staff writers. April 23, 2020 04:00 PM Eastern Daylight Time. To demonstrate our dedication to patients and our understanding of the importance of clinical trials, we have created a . ITI maintains its headquarters in Rockville, Maryland. Work Here? As a result, a robust T cell response by both CD4+ and CD8+ T cells is expected to drive antitumor activity of this product. The foundation of a successful company is only as strong as the quality of its employee team. Nature. ITI Media: Animal Health All. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Equal Opportunity: ITI is committed to creating a diverse environment and is proud to be an Equal Opportunity Employer. Seed, Series A, Private Equity), Whether an Organization is for profit or non-profit, General contact email for the organization. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000, a pDNA Vaccine, in Development for the Treatment of Merkel Cell Carcinoma November 08, 2022 08:30 AM Eastern Standard Time The company was founded in 2005 and is based in Lancaster, Pennsylvania. Case Study: Immunomic Therapeutics - Nature Research Partnerships Handled COVID very well.